# Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

> **NCT02518698** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1163 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT02518698
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-31
- **Primary completion:** 2017-09-30
- **Final completion:** 2017-09-30
- **Target enrollment:** 1163 (ACTUAL)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02518698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02518698, "Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02518698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*